Leo's intro email for today's announcement: "Go
Post# of 72447
(Total Views: 553)
Posted On: 07/22/2019 11:17:03 AM
Leo's intro email for today's announcement:
"Good morning!
I am very excited to start the week by informing our shareholders that we have successfully executed a new partnership with Alfasigma S.p.A, a global pharmaceutical company employing over 3,000 people and generating annual revenue in excess of €1 billion, for the purpose of developing Brilacidin for UP/UPS.
This is a major milestone for us and lends a tremendous amount of validation to the platform potential of Brilacidin as the flagship compound in a new class of drugs, defensin-mimetics. The partnership provides us access to initial and milestone-based capital, and also frees up valuable resources to aggressively develop oral Brilacidin for the much larger Ulcerative Colitis market, as well as advance oral rinse Brilacidin in Oral Mucositis.
We believe that we are well positioned as drug development leaders in both of these markets and are thrilled with the Alfasigma partnership as it will help us build shareholder value and fulfill our goals of penetrating multibillion dollar markets, bringing needed treatments to patients.
Please take a moment to read the full press release below."
"Good morning!
I am very excited to start the week by informing our shareholders that we have successfully executed a new partnership with Alfasigma S.p.A, a global pharmaceutical company employing over 3,000 people and generating annual revenue in excess of €1 billion, for the purpose of developing Brilacidin for UP/UPS.
This is a major milestone for us and lends a tremendous amount of validation to the platform potential of Brilacidin as the flagship compound in a new class of drugs, defensin-mimetics. The partnership provides us access to initial and milestone-based capital, and also frees up valuable resources to aggressively develop oral Brilacidin for the much larger Ulcerative Colitis market, as well as advance oral rinse Brilacidin in Oral Mucositis.
We believe that we are well positioned as drug development leaders in both of these markets and are thrilled with the Alfasigma partnership as it will help us build shareholder value and fulfill our goals of penetrating multibillion dollar markets, bringing needed treatments to patients.
Please take a moment to read the full press release below."
(11)
(0)